NASDAQ:GBT

Global Blood Therapeutics Stock Forecast, Price & News

$26.89
-0.86 (-3.10 %)
(As of 08/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.15
$27.72
50-Day Range
$26.89
$41.67
52-Week Range
$26.15
$70.43
Volume1.10 million shs
Average Volume1.04 million shs
Market Capitalization$1.67 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.01
30 days | 90 days | 365 days | Advanced Chart
Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Global Blood Therapeutics logo

About Global Blood Therapeutics

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.12 out of 5 stars

Medical Sector

433rd out of 1,309 stocks

Pharmaceutical Preparations Industry

218th out of 646 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

Is Global Blood Therapeutics a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Global Blood Therapeutics stock.
View analyst ratings for Global Blood Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Global Blood Therapeutics?

Wall Street analysts have given Global Blood Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Global Blood Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) announced its quarterly earnings results on Tuesday, May, 4th. The company reported ($1.21) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by $0.20. The company earned $39.04 million during the quarter, compared to analysts' expectations of $42.88 million. Global Blood Therapeutics had a negative trailing twelve-month return on equity of 57.58% and a negative net margin of 167.73%.
View Global Blood Therapeutics' earnings history
.

How has Global Blood Therapeutics' stock price been impacted by Coronavirus?

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GBT shares have decreased by 51.0% and is now trading at $26.89.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GBT?

15 equities research analysts have issued twelve-month target prices for Global Blood Therapeutics' stock. Their forecasts range from $36.00 to $152.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $80.50 in the next twelve months. This suggests a possible upside of 199.4% from the stock's current price.
View analysts' price targets for Global Blood Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:
  • Ted W. Love, President, Chief Executive Officer & Director
  • Nazila Habibizad, Senior Vice President-Operations
  • Jeffrey S. Farrow, Chief Financial & Accounting Officer
  • Kim Smith-Whitley, Executive VP, Head-Research & Development
  • Jung E. Choi, Chief Business & Strategy Officer

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

13 employees have rated Global Blood Therapeutics CEO Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among Global Blood Therapeutics' employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Global Blood Therapeutics' key competitors?

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Square (SQ).

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.56%), Granite Investment Partners LLC (0.16%), Alliancebernstein L.P. (0.12%), New York State Common Retirement Fund (0.08%), Zurcher Kantonalbank Zurich Cantonalbank (0.05%) and Oppenheimer & Co. Inc. (0.03%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends for Global Blood Therapeutics
.

Which major investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, New York State Common Retirement Fund, Zurcher Kantonalbank Zurich Cantonalbank , Arizona State Retirement System, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Eric Fink, and Philip A Pizzo.
View insider buying and selling activity for Global Blood Therapeutics
or view top insider-selling stocks.

Which major investors are buying Global Blood Therapeutics stock?

GBT stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Woodward Diversified Capital LLC, Oppenheimer & Co. Inc., Granite Investment Partners LLC, Victory Capital Management Inc., and Cutler Group LP. Company insiders that have bought Global Blood Therapeutics stock in the last two years include Eric Fink, and Willie L Jr Brown.
View insider buying and selling activity for Global Blood Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $26.89.

How much money does Global Blood Therapeutics make?

Global Blood Therapeutics has a market capitalization of $1.67 billion and generates $123.80 million in revenue each year. The company earns $-247,550,000.00 in net income (profit) each year or ($4.04) on an earnings per share basis.

How many employees does Global Blood Therapeutics have?

Global Blood Therapeutics employs 389 workers across the globe.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is www.gbt.com.

Where are Global Blood Therapeutics' headquarters?

Global Blood Therapeutics is headquartered at 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 741-7700 or via email at [email protected]


This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.